P3 Health Partners Inc. - Class A Common Stock (PIII)

P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQPIII), a patient-centered and physician-led population health management company, today announced it will participate at the upcoming J.P. Morgan Healthcare Conference in San Francisco, California.

P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQPIII), a patient-centered and physician-led population health management company, today announced that management is scheduled to present at the Noble Capital Markets 20th Annual Emerging Growth Equity Conference, on Tuesday, December 3, 2024, in Boca Raton, FL, at 3:30 pm Eastern Time.

P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQPIII), a patient-centered and physician-led population health management company, today announced the Company will participate in the following upcoming investor conferences:

P3 Health Partners (NASDAQPIII) is revolutionizing healthcare by focusing on improving patient outcomes through value-based care. The company will be presenting alongside world-class headliners such as Zack Kass, former Head of Go-To-Market at OpenAI where ChatGPT was created, and “Shark Tank” stars Kevin O’Leary, Robert Herjavec, and Daymond John.

P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQPIII), a patient-centered and physician-led population health management company, today announced its financial results for the third quarter ended September 30, 2024.

P3 Health Partners Inc. (“P3”) (NASDAQPIII), a patient-centered and physician-led population health management company, today announced that the Company plans to release its financial results for third quarter 2024 and file its Quarterly Report on Form 10-Q on Tuesday, November 12, 2024. In connection with the release, management will host a conference call to discuss the financial results at 1:30pm PT/ 4:30pm ET the same day.

P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQPIII), a patient-centered and physician-led population health management company, today announced that management is scheduled to present at the LD Micro Main Event XVII Conference on Wednesday, October 30, 2024, in Los Angeles, CA, at 2:30 pm Eastern Time.

P3 Health Partners Inc. ("P3") (NASDAQPIII), a patient-centered and physician-led population health management company, announced today that Leif Pedersen, an experienced finance, operational and value-based care executive, will join the company as chief financial officer (CFO) effective October 1, 2024. Pedersen succeeds Atul Kavthekar, who will continue as CFO until September 30, 2024, after which he will serve as a Strategic Advisor to the company.

P3 Health Partners Inc. (“P3”) (NASDAQPIII), a patient-centered and physician-led population health management company will participate at the following upcoming investor conferences:

P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQPIII), a patient-centered and physician-led population health management company, today announced its financial results for the second quarter ended June 30, 2024.

P3 Health Partners Inc. (“P3”) (NASDAQPIII), a patient-centered and physician-led population health management company, today announced that the Company plans to release its financial results for second quarter 2024 and file its Quarterly Report on Form 10-Q on Wednesday, August 7, 2024. In connection with the release, management will host a conference call to discuss the financial results at 1:30pm PT/ 4:30pm ET the same day.

Innovaccer Inc., a leading healthcare AI company, announced a new strategic partnership with P3 Health Partners, (NASDAQPIII), a patient-centered, physician-led population health management company revolutionizing care delivery for Medicare patients. This partnership marks a significant milestone in advancing value-based care initiatives aimed at improving patient outcomes, optimizing costs, and enhancing the patient and clinician experience.

P3 Health Partners Inc. (“P3”) (NASDAQPIII), a patient-centered and physician-led population health management company, will participate at the following upcoming investor conferences:

P3 Health Partners Inc. (Nasdaq: PIII), a patient- centered and physician-led population health management company (the “Company”), today announced that it has entered into definitive agreements to sell securities in a private placement with certain institutional investors. The lead institutional investors in the private placement are affiliates of Chicago Pacific Founders (“CPF”). The transaction is expected to result in gross proceeds of approximately $42.2 million, including approximately $20.0 million of gross proceeds from purchases by affiliates of CPF, before deducting placement agent fees and offering expenses.

P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQPIII), today reported that the Board of Directors (the “Board”) (including the independent members of the Board) approved the award of employment inducement equity grants to Aric Coffman, M.D. in connection with his agreement to serve as the Company’s Chief Executive Officer and President as follows: effective as of May 9, 2024, the grant of an employment inducement stock option award covering 12,100,000 Class A shares of P3’s common stock, par value $0.0001 (the “Common Stock”), and an employment inducement restricted stock unit (RSU) award covering 4,400,000 shares of Common Stock. The stock option will vest and become exercisable over a four-year period with respect to 25% of the shares subject to the option on the first anniversary of the effective date of Dr. Coffman’s employment, and with respect to the remaining 75% of the shares subject to the option in substantially equal installments on each three-month anniversary over the three (3)-year period thereafter, subject to Dr. Coffman’s continued employment with P3 through the applicable vesting date. The RSU award will be subject to both service-vesting and performance-vesting conditions, such that both conditions must be met for the RSU award to vest, subject to Dr. Coffman’s continued employment with P3 through the applicable vesting date. The service-vesting condition will follow the same vesting schedule as the stock option. The performance-vesting condition will be satisfied upon the closing of P3’s first underwritten offering and sale of its Common Stock. The awards were granted under P3’s 2024 Employment Inducement Incentive Award Plan as employment inducement awards in accordance with Nasdaq Listing Rule 5635(c)(4).

P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQPIII), today named Dr. Aric Coffman as P3’s Chief Executive Officer, effective as of May 8, 2024, succeeding Dr. Sherif Abdou, P3’s Co-Founder. Dr. Abdou will continue to serve as a Strategic Advisor to P3, and a member of the Company’s Board of Directors working closely with Dr. Coffman to ensure a smooth transition.

P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQPIII), a patient-centered and physician-led population health management company, today announced its financial results for the first quarter ended March 31, 2024.

P3 Health Partners Inc. (“P3”) (NASDAQPIII), a patient-centered and physician-led population health management company, today announced that the Company plans to release its financial results for first quarter 2024 and file its Quarterly Report on Form 10-Q on Wednesday, May 8, 2024. In connection with the release, management will host a conference call to discuss the financial results at 1:30pm PT/ 4:30pm ET the same day.

P3 Health Partners Inc. (“P3”) (NASDAQPIII), a patient-centered and physician-led population health management company, today announced that management is scheduled to present at the 23rd Annual Needham Virtual Healthcare Conference on Thursday, April 11, 2024, at 1:30 pm Eastern Time.

P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQPIII), a patient-centered and physician-led population health management company, today announced its financial results for the fourth quarter and full year ended December 31, 2023, and affirmed its 2024 guidance.

P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQPIII), a patient-centered and physician-led population health management company, announces that the Company plans to release its financial results for the fourth quarter and full year 2023 on March 28, 2024 and is reaffirming its 2024 guidance.

P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQPIII), a patient-centered and physician-led population health management company, today announced that leadership is scheduled to present at the KeyBanc LifeSciences & Medtech Investor Forum virtually on Tuesday, March 19, 2024 at 3:45pm ET.

P3 Health Partners Inc. (“P3”) (NASDAQPIII), a patient-centered and physician-led population health management company, today announced management will participate in the upcoming Jefferies Value Based Healthcare Summit in Miami Beach, Florida.

P3 Health Partners Inc. (“P3”) (NASDAQPIII), a patient-centered and physician-led population health management company, today announced that management is scheduled to present at the TD Cowen 44th Annual Health Care Conference in Boston on Monday, March 4, 2024 at 10:30 am Eastern Time.

P3 Health Partners Inc. (“P3”) (NASDAQPIII), a patient-centered and physician-led population health management company, today announced that it will participate in the upcoming 2024 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference in Snowbird, Utah.